Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
29
PPH Quote, Financials, Valuation and Earnings
Last price:
$86.61
Seasonality move
:
2.83%
Day range:
$85.97 - $87.24
52-week range:
$80.52 - $99.51
Dividend yield:
1.86%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
193.4K
Avg. volume:
194.9K
1-year change:
8.84%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
IYH
iShares US Healthcare ETF
|
-- | -- | -- | -- | -- |
|
VHT
Vanguard Health Care Index Fund ETF
|
-- | -- | -- | -- | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
$86.54 | -- | -- | -- | $0.41 | 1.86% | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
$65.41 | -- | -- | -- | $0.26 | 1.51% | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
$65.71 | -- | -- | -- | $0.21 | 1.73% | -- |
|
IYH
iShares US Healthcare ETF
|
$58.30 | -- | -- | -- | $0.20 | 1.25% | -- |
|
VHT
Vanguard Health Care Index Fund ETF
|
$253.89 | -- | -- | -- | $0.92 | 1.52% | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
$138.00 | -- | -- | -- | $0.58 | 1.65% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.750 | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | 1.049 | -- | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
-- | 1.040 | -- | -- |
|
IYH
iShares US Healthcare ETF
|
-- | 0.983 | -- | -- |
|
VHT
Vanguard Health Care Index Fund ETF
|
-- | 1.066 | -- | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
-- | 0.981 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
IYH
iShares US Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
VHT
Vanguard Health Care Index Fund ETF
|
-- | -- | -- | -- | -- | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
-- | -- | -- | -- | -- | -- |
VanEck Pharmaceutical ETF vs. Competitors
-
Which has Higher Returns PPH or FHLC?
Fidelity MSCI Health Care Index ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat Fidelity MSCI Health Care Index ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- -
What do Analysts Say About PPH or FHLC?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity MSCI Health Care Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than Fidelity MSCI Health Care Index ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than Fidelity MSCI Health Care Index ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 FHLCFidelity MSCI Health Care Index ETF0 0 0 -
Is PPH or FHLC More Risky?
VanEck Pharmaceutical ETF has a beta of 0.666, which suggesting that the stock is 33.432% less volatile than S&P 500. In comparison Fidelity MSCI Health Care Index ETF has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.734%.
-
Which is a Better Dividend Stock PPH or FHLC?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.86%. Fidelity MSCI Health Care Index ETF offers a yield of 1.51% to investors and pays a quarterly dividend of $0.26 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. Fidelity MSCI Health Care Index ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or FHLC?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than Fidelity MSCI Health Care Index ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than Fidelity MSCI Health Care Index ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while Fidelity MSCI Health Care Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for Fidelity MSCI Health Care Index ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- --
-
Which has Higher Returns PPH or IHE?
iShares US Pharmaceuticals ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat iShares US Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- IHEiShares US Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PPH or IHE?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than iShares US Pharmaceuticals ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than iShares US Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 IHEiShares US Pharmaceuticals ETF0 0 0 -
Is PPH or IHE More Risky?
VanEck Pharmaceutical ETF has a beta of 0.666, which suggesting that the stock is 33.432% less volatile than S&P 500. In comparison iShares US Pharmaceuticals ETF has a beta of 0.656, suggesting its less volatile than the S&P 500 by 34.431%.
-
Which is a Better Dividend Stock PPH or IHE?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.86%. iShares US Pharmaceuticals ETF offers a yield of 1.73% to investors and pays a quarterly dividend of $0.21 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. iShares US Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or IHE?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than iShares US Pharmaceuticals ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than iShares US Pharmaceuticals ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while iShares US Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for iShares US Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- IHEiShares US Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PPH or IYH?
iShares US Healthcare ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat iShares US Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- IYHiShares US Healthcare ETF-- -- -- -
What do Analysts Say About PPH or IYH?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than iShares US Healthcare ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than iShares US Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 IYHiShares US Healthcare ETF0 0 0 -
Is PPH or IYH More Risky?
VanEck Pharmaceutical ETF has a beta of 0.666, which suggesting that the stock is 33.432% less volatile than S&P 500. In comparison iShares US Healthcare ETF has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.453%.
-
Which is a Better Dividend Stock PPH or IYH?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.86%. iShares US Healthcare ETF offers a yield of 1.25% to investors and pays a quarterly dividend of $0.20 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. iShares US Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or IYH?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than iShares US Healthcare ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than iShares US Healthcare ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while iShares US Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for iShares US Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- IYHiShares US Healthcare ETF-- -- -- --
-
Which has Higher Returns PPH or VHT?
Vanguard Health Care Index Fund ETF has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat Vanguard Health Care Index Fund ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- VHTVanguard Health Care Index Fund ETF-- -- -- -
What do Analysts Say About PPH or VHT?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Vanguard Health Care Index Fund ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than Vanguard Health Care Index Fund ETF, analysts believe VanEck Pharmaceutical ETF is more attractive than Vanguard Health Care Index Fund ETF.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 VHTVanguard Health Care Index Fund ETF0 0 0 -
Is PPH or VHT More Risky?
VanEck Pharmaceutical ETF has a beta of 0.666, which suggesting that the stock is 33.432% less volatile than S&P 500. In comparison Vanguard Health Care Index Fund ETF has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.236%.
-
Which is a Better Dividend Stock PPH or VHT?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.86%. Vanguard Health Care Index Fund ETF offers a yield of 1.52% to investors and pays a quarterly dividend of $0.92 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. Vanguard Health Care Index Fund ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or VHT?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than Vanguard Health Care Index Fund ETF quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than Vanguard Health Care Index Fund ETF's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while Vanguard Health Care Index Fund ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for Vanguard Health Care Index Fund ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- VHTVanguard Health Care Index Fund ETF-- -- -- --
-
Which has Higher Returns PPH or XLV?
Health Care Select Sector SPDR Fund has a net margin of -- compared to VanEck Pharmaceutical ETF's net margin of --. VanEck Pharmaceutical ETF's return on equity of -- beat Health Care Select Sector SPDR Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPHVanEck Pharmaceutical ETF-- -- -- XLVHealth Care Select Sector SPDR Fund-- -- -- -
What do Analysts Say About PPH or XLV?
VanEck Pharmaceutical ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Health Care Select Sector SPDR Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Pharmaceutical ETF has higher upside potential than Health Care Select Sector SPDR Fund, analysts believe VanEck Pharmaceutical ETF is more attractive than Health Care Select Sector SPDR Fund.
Company Buy Ratings Hold Ratings Sell Ratings PPHVanEck Pharmaceutical ETF0 0 0 XLVHealth Care Select Sector SPDR Fund0 0 0 -
Is PPH or XLV More Risky?
VanEck Pharmaceutical ETF has a beta of 0.666, which suggesting that the stock is 33.432% less volatile than S&P 500. In comparison Health Care Select Sector SPDR Fund has a beta of 0.672, suggesting its less volatile than the S&P 500 by 32.764%.
-
Which is a Better Dividend Stock PPH or XLV?
VanEck Pharmaceutical ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.86%. Health Care Select Sector SPDR Fund offers a yield of 1.65% to investors and pays a quarterly dividend of $0.58 per share. VanEck Pharmaceutical ETF pays -- of its earnings as a dividend. Health Care Select Sector SPDR Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPH or XLV?
VanEck Pharmaceutical ETF quarterly revenues are --, which are smaller than Health Care Select Sector SPDR Fund quarterly revenues of --. VanEck Pharmaceutical ETF's net income of -- is lower than Health Care Select Sector SPDR Fund's net income of --. Notably, VanEck Pharmaceutical ETF's price-to-earnings ratio is -- while Health Care Select Sector SPDR Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Pharmaceutical ETF is -- versus -- for Health Care Select Sector SPDR Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPHVanEck Pharmaceutical ETF-- -- -- -- XLVHealth Care Select Sector SPDR Fund-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
